Drew Moghanaki 🐕 @DrewMoghanaki Twitter profile

Pinned Tweet

Drew Moghanaki 🐕

2 years

If you know ANYONE who used to smoke, or is still smoking, please have them watch this 1-minute VIDEO. It could save their life. #lcsm

10

25

93

Last Seen Profiles

@Coach_DougGove

@AwesomeFursuits

@345Gj

@VBlossomga27408

@OniricFactor

@ScheckNYTimes

@B6QtNV7FHCPoDVN

@SusieKatha45904

@orgkokgini

@etztl

@hydrokisser

@Onoe_Akira

@GArgetsing60863

@SpringerMuse

@CRAOL

@Sue_chwan

@AndaLookkaew_CN

@chatrandom

@soro

@runawaypacy

@Pecintastw4050

@fenwickfriars

@AshleyCahi64372

@t_nobuki_MI

@Neify_fn7

@smb_tradebot

@Nathaneelliott1

@Mai904710248801

@Werty_02

@Aik30068733Aik

@codenamekyle

@ixxi_tg

@v4gbRo9tZRkhk4

@Effymom

@DAIKING_staff

@gibril2t

Drew Moghanaki 🐕

@DrewMoghanaki

1 year

The standard of care for stage IA NSCLC can now officially change. [Ref: CALGB 140503] #lcsm

12

155

444

Drew Moghanaki 🐕

@DrewMoghanaki

4 years

A Canadian radiation oncologist with more energy than anyone I know completes a practice-changing randomized trial that shows SBRT for spine metastases DOUBLES the CR rate. As long as it's delivered in TWO fractions (not one). 🇨🇦 #ASTRO20 #radonc @SahgalArjun

13

105

306

Drew Moghanaki 🐕

@DrewMoghanaki

1 year

BREAKING: A new randomized trial demonstrates the benefit of SBRT for patients with EGFR+ stage IV NSCLC. It demonstrates both PFS and OS benefits (n=62). 🇨🇳 #radonc @EGFRResisters @jillfeldman4

7

90

237

Drew Moghanaki 🐕

@DrewMoghanaki

1 year

I'd like to emphasize that @_ShankarSiva has set a new bar for preparing a talk. He used images derived using AI, and the transitions were simply spectacular. #ESTRO23 #radonc

7

24

218

Drew Moghanaki 🐕

@DrewMoghanaki

2 years

A new report from @_ShankarSiva shows why TOTAL METASTATIC ABLATION is preferred whenever feasible. #radonc 1/

9

73

174

Drew Moghanaki 🐕

@DrewMoghanaki

3 years

Still don't believe in the power of cancer advocacy? This bill was just signed by our governor. It declares that it will soon be a CRIME for an insurance company in California to deny biomarker testing for stage III or IV cancer. #lcsm #radonc

10

34

163

Drew Moghanaki 🐕

@DrewMoghanaki

3 years

The next time that someone in the Ivory Tower perseverates over the value of studies that rely merely on a PFS signal, please share this slide that @jillfeldman4 created which sheds light on what patients often endure to get that PFS signal. #lcsm #radonc

3

45

156

Drew Moghanaki 🐕

@DrewMoghanaki

2 years

The Timmerman Files are finally published, along with the confession "In all honesty, except for the spinal cord, all other limits for this original table were my educated guesses". #radonc

7

48

156

Drew Moghanaki 🐕

@DrewMoghanaki

6 years

As we’ve got a series of British speakers at #ASTRO18 , a primer is needed for us Americans to understand why they really mean. 🇬🇧

9

47

148

Drew Moghanaki 🐕

@DrewMoghanaki

11 months

I know at least a dozen radiation oncologists who have worried for decades that IMRT would increase the risk of secondary cancers compared to conventional 3DCRT. A SEER-linked Mediare study of 65,235 patients with at least 2 years of survival now tells us this. #radonc

7

48

148

Drew Moghanaki 🐕

@DrewMoghanaki

5 months

The VALOR study has now officially enrolled 50% of its planned accrual of 670 participants. We are truly grateful to all of the US Veterans with operable stage I lung cancer who are volunteering to participate in this study. @VAResearch #CSP2005

VA.gov | Veterans Affairs

Apply for and manage the VA benefits and services you’ve earned as a Veteran, Servicemember, or family member—like health care, disability, education, and more.

www.vacsp.research.va.gov

11

17

140

Drew Moghanaki 🐕

@DrewMoghanaki

3 months

This surgeon once taught me to be aware of bullies who use phrases like, "Surgery remains the standard of care". He taught me that it's more accurate to say, "We have historically preferred surgery", and then explain why. He also pioneered the field of Surgical Oncology.

4

17

139

Drew Moghanaki 🐕

@DrewMoghanaki

7 months

How is it possible that the only 3 prospective comparison studies of Surgery v SBRT for operable stage I NSCLC show similar to superior outcomes after SBRT, yet the @NCCN guidelines don’t even mention SBRT as an option for this population? #radonc

Drew Moghanaki 🐕

@DrewMoghanaki

8 months

NEW STUDY: another prospective cohort study comparing Surgery to SBRT for stage IA NSCLC shows no difference in CSS or OS (median f/u = 57.6 months). #radonc

3

37

97

9

33

127

Drew Moghanaki 🐕

@DrewMoghanaki

2 years

The ProtecT team releases another analysis that shows what happened to 2,565 men with prostate cancer who were randomly assigned to receive surgery, radiation therapy, or active monitoring. #pcsm #radonc @QuinteTBristol

3

55

133

Drew Moghanaki 🐕

@DrewMoghanaki

2 years

I was just informed that the Final Results of the largest phase III lung SBRT trial that few have heard about may be presented at #ASTRO22 . 🇨🇦 #radonc #lcsm

5

30

129

Drew Moghanaki 🐕

@DrewMoghanaki

6 months

This list continues to expand and now includes the BRAF BOMBERS! Make sure to save a copy of this photo on your phone and share it with any patient with one of the following mutations so they can find their tribe. #radonc

2

46

128

Drew Moghanaki 🐕

@DrewMoghanaki

2 years

The 8,000 mile journey is finally complete to personally deliver a White Ribbon to @_ShankarSiva . #radonc

6

5

123

Drew Moghanaki 🐕

@DrewMoghanaki

3 years

Here's my favorite slide for tonight's talk [slide #23 ]. #lcsm #radonc Register:

5

28

123

Drew Moghanaki 🐕

@DrewMoghanaki

6 months

Is this real or AI generated?

20

11

119

Drew Moghanaki 🐕

@DrewMoghanaki

5 years

This might be the largest gathering of lung cancer survivors in their 20’s and 30’s, ever assembled in the world. #ILCSC19 #lcsm @IASLC

5

18

117

Drew Moghanaki 🐕

@DrewMoghanaki

11 months

3

46

113

Drew Moghanaki 🐕

@DrewMoghanaki

6 years

Here’s a license plate I saw during a recent trip to Atlanta. Doubtful it belongs to a radiation oncologist. #radonc #pcsm

7

13

115

Drew Moghanaki 🐕

@DrewMoghanaki

1 year

Radiosurgery for Refractory Depression likely saved the lives of patients who participated in this IRB-approved clinical trial. Treatment target = bilateral anterior limb of the internal capsule) #radonc

2

37

112

Drew Moghanaki 🐕

@DrewMoghanaki

3 months

The standard of care for stage III NSCLC changes once again; Say goodbye to Durvalumab for patients with mEGFR (ex19del & L858R). #radonc

7

38

112

Drew Moghanaki 🐕

@DrewMoghanaki

11 months

Kudos to @TheLancet for publishing this seminal randomized study demonstrating Nivolumab's benefit in eradicating invisible tumors that our PET/CT, EBUS biopsies, and SBRT beams can't see. I'm curious why it didn't get submitted or published in NEJM instead. #radonc

5

24

111

Drew Moghanaki 🐕

@DrewMoghanaki

2 years

New Zealand’s Prime Minister, Jacinda Arden, announces their country’s investment in 12 new linacs for patients with cancer. 🇳🇿 #radonc @PhilipHope19 VIDEO:

2

17

111

Drew Moghanaki 🐕

@DrewMoghanaki

1 month

A nationwide Dutch study (ESLUNG) demonstrates similar OS for stage I NSCLC treated with Lobectomy or SABR (HR 0.89, 95 % CI 0.65–1.20). #radonc #CSP2005

4

39

112

Drew Moghanaki 🐕

@DrewMoghanaki

4 years

A proton therapy plan for a woman with breast cancer who has a big heart. ❤️ #radonc #bcsm

7

16

111

Drew Moghanaki 🐕

@DrewMoghanaki

1 year

The Dutch lung cancer team from Amsterdam strikes again. This time shedding light on a "One Stop Shop" program for lung SBRT. 🇳🇱 #radonc @FJLagerwaard @SchneidersFamke @bslotman

3

21

111

Drew Moghanaki 🐕

@DrewMoghanaki

10 months

A multi-disciplinary team of thoracic oncologists at UCLA takes the liberty to publish an editorial inspired by @JackWestMD . #radonc @IASLC @JTOonline

10

17

110

Drew Moghanaki 🐕

@DrewMoghanaki

4 years

Today’s update on randomized trials investigating the life-prolonging value of SBRT for people with stage IV lung cancer. #ASCO20 #lcsm #radonc

4

33

107

Drew Moghanaki 🐕

@DrewMoghanaki

2 months

🇺🇸 Wishing a safe and uneventful military deployment for our friend and colleague, @EvanThomas84 , who will spend the next few weeks in Iraq. #radonc

5

11

108

Drew Moghanaki 🐕

@DrewMoghanaki

1 year

Chairman: "Is thoracic RT safe with osimertinib"? Me and @claysmithmd : let's find out with our medical oncologists. Manuscript:

5

31

104

Drew Moghanaki 🐕

@DrewMoghanaki

5 years

Worried about the efficacy of a treatment in a study? Think you can deliver better care than a clinical trial team? If so, then you might want to think about this before surrendering to your gut instinct. #radonc

10

32

102

Drew Moghanaki 🐕

@DrewMoghanaki

1 year

This SPECTACULAR phase III randomized clinical trial was once thought impossible to complete. How did they do it? By inviting a medical anthropologist (Jenny Donovan at @QuinteTBristol ) to help design and lead the study.

4

32

104

Drew Moghanaki 🐕

@DrewMoghanaki

9 months

🔥 ALERT: A new study shows an OS benefit with concurrent Tumor Treating Fields for patients with metastatic NSCLC. #lcsm @jillfeldman4

8

38

103

Drew Moghanaki 🐕

@DrewMoghanaki

3 years

While the non-believers were arguing and debating the 2015 @TheLancetOncol publication of the STARS-ROSEL pooled analysis, the SBRT cohort at MD Anderson was expanded to n=80 by @JoeChangMD et. al. to finally get us the 5y OS data (87%). #radonc #lcsm

5

48

102

Drew Moghanaki 🐕

@DrewMoghanaki

4 years

One of the nicest thoracic radiation oncologists I know was just appointed Chair at City of Hope. Congrats Terry! I'm sure that David Carbone and many others will sorely miss you. #radonc #lcsm @cityofhope

15

5

101

Drew Moghanaki 🐕

@DrewMoghanaki

1 year

Updated results from SAFRON-II will be presented this Sunday at #ESTRO23 , once again demonstrating the value of single-fraction SBRT for oligomets (28 Gy x 1 versus 12 Gy x 4). #radonc @_ShankarSiva

5

36

100

Drew Moghanaki 🐕

@DrewMoghanaki

2 years

Results from DOLPHIN were just reported and give us the first signal of what can happen when Durvalumab is delivered with concurrent CRT. #WCLC2022 #radonc 1/

6

43

98

Drew Moghanaki 🐕

@DrewMoghanaki

8 months

NEW STUDY: another prospective cohort study comparing Surgery to SBRT for stage IA NSCLC shows no difference in CSS or OS (median f/u = 57.6 months). #radonc

3

37

97

Drew Moghanaki 🐕

@DrewMoghanaki

2 years

The SPCG-15 is randomizing 1,200 men between Surgery and RT for high-risk prostate cancer. The characteristics of the first 600 patients enrolled is now published. #radonc #pcsm

3

26

99

Drew Moghanaki 🐕

@DrewMoghanaki

2 years

27 years after the LCSG 821 randomized trial established lobectomy as the standard of care, a contemporary randomized trial (JCOG0802, n=1,106) now informs us that segmentectomy offers superior survival for stage I NSCLC tumors ≤2 cm. #radonc #lcsm

4

28

98

Drew Moghanaki 🐕

@DrewMoghanaki

5 years

It's incredible what radiotherapy can do to help people with lung cancer live even LONGER, as we sort out how best to deliver it. #radonc #lcsm #stateofscience @aesfCEO @OncLiveSOSS

8

55

96

Drew Moghanaki 🐕

@DrewMoghanaki

4 years

Why do so many journal reviewers not understand the boundaries of retrospective studies of observational data? This highlighted word is incorrect. Needs to be replaced with "IS ASSOCIATED WITH". #radonc #lcsm @BrendonStilesMD @biniamkidaneMD

11

15

96

Drew Moghanaki 🐕

@DrewMoghanaki

1 year

Published today:

Shankar Siva

@_ShankarSiva

1 year

🧵2/ Metastasis-directed Tx to the 🫁 has limited trial evidence (surgery or SABR). Whilst convenient, popular during #COVID19 , there is reluctance for single fraction fraction 🥊 SABR for perceived toxicity. @TROGfightcancer SAFRON II randomised n=90 with 133 🫁 mets to 1 vs 4fx

10

76

196

2

43

96

Drew Moghanaki 🐕

@DrewMoghanaki

1 year

Here's what happened at an advanced #radonc department with the most sophisticated equipment in the world (MRIdian, Protons, etc) after it opted to Drop the Sim.

7

23

96

Drew Moghanaki 🐕

@DrewMoghanaki

4 years

What a time to be a radiation oncologist. One becomes the FDA Commissioner, and another discovers a new vital sign for people with lung cancer! #lcam #lcsm #radonc

Montefiore Health System

@MontefioreNYC

4 years

How can your step count predict lung cancer treatment outcomes? Dr. Nitin Ohri's newest research found the powerful implications of this data: @ASTRO_org #LCSM #RadOnc @LUNGevity @LUNGFORCE #RedJournal

5

19

39

2

17

95

Drew Moghanaki 🐕

@DrewMoghanaki

3 years

Perfect choice. Congratulations! 👏👏 👏👏 @sueyom #radonc

6

10

91

Drew Moghanaki 🐕

@DrewMoghanaki

2 years

Here are the officially announced president elects of the European (ESTRO) and American (ASTRO) Societies of Radiation Oncology at #ESTRO2022 . #radonc @ESTRO_RT @ASTRO_org

3

7

91

Drew Moghanaki 🐕

@DrewMoghanaki

5 months

A thoracic surgeon publishes the results of a randomized clinical trial in Nature Communications demonstrating the effects of SBRT before surgery when combined with a checkpoint inhibitor. @AltorkiNasser

3

26

90

Drew Moghanaki 🐕

@DrewMoghanaki

3 years

Came in early on my last day at the Atlanta VA before anyone else arrived to see this. I’m gonna miss them all. I was very lucky to work with amazing people who were all committed to a single mission of excellence for our Veterans with cancer. #radonc

5

1

90

Drew Moghanaki 🐕

@DrewMoghanaki

3 years

The Dutch are now curing stage I NSCLC in a median of 120 minutes. Can a lobectomy or wedge be performed any more quickly? @bslotman #radonc

6

24

89

Drew Moghanaki 🐕

@DrewMoghanaki

2 years

Warning: be suspicious of radiation, medical, and surgical oncologists who blindly professes surgery’s superiority over chemoradiation for stage IIIA (N2) NSCLC. Especially if they reference the RTOG 9309 / INT 0139 study. A THREAD 1/

Radiotherapy plus Chemotherapy with or without Surgical Resection for Stage III Non-Small Cell Lung...

Concurrent chemotherapy plus radiation therapy (chemoRT) is the standard treatment for stage IIIA(N2) non-small cell lung cancer (NSCLC), a common disease entity. Phase II studies demonstrated...

www.ncbi.nlm.nih.gov

6

26

87

Drew Moghanaki 🐕

@DrewMoghanaki

5 years

The largest randomized clinical trial ever attempted by the RTOG has finally completed accrual (n=2,580). #radonc

1

24

84

Drew Moghanaki 🐕

@DrewMoghanaki

7 months

This is huge. Potentially an even bigger setback than RTOG 0617. The implications of these results cannot be overstated. We should have listened more to the translational radiation oncologists who predicted this outcome. @KaramLab @JieDengMDPhD @max_diehn @theabzlab @SeanPitroda

Stephen V Liu, MD

@StephenVLiu

7 months

PACIFIC-2 does not meet PFS endpoint. Phase III study of concurrent chemoradiation + duvalumab vs CRT alone for stage III NSCLC. Toxicity? Negative interaction? Or due to intrinsically different population: PACIFIC enrolled only those who completed CRT.

15

68

219

7

30

87

Drew Moghanaki 🐕

@DrewMoghanaki

4 years

Within days of FDA's approval of Nivo + Ipi for 1st Line metastatic NSCLC, we quickly learn that adding upfront multisite SBRT to this combination might help people live even longer. @Docace911 @n8pennell @JackWestMD @VPrasadMDMPH #ASCO20 #radonc #lcsm

3

33

87

Drew Moghanaki 🐕

@DrewMoghanaki

4 years

Many already know how amazing @christine_lovly is and the value she continues to add to the lung cancer community. She is now contributing even more as a member of the @LUNGevity Scientific Advisory Board. #lcsm

1

7

86

Drew Moghanaki 🐕

@DrewMoghanaki

4 years

Whenever people state "It's not fair for a non-smoker to get lung cancer" it simultaneously implies that smokers deserve to get lung cancer. I learned this, and many other pearls, from the clairvoyant and simply charming @jillfeldman4 . #WorldLungCancerDay #lcsm #lcam #radonc

3

11

85

Drew Moghanaki 🐕

@DrewMoghanaki

6 years

When they go low, we go high.

9

0

86

Drew Moghanaki 🐕

@DrewMoghanaki

1 year

The Canadian group that brought us 4 Gy x 15 for stage I NSCLC now report their experience with this Rx for central lung tumors (n=111). 🇨🇦 #radonc @DrPatCheung @DrAlexLouie 1/🧵

1

22

84

Drew Moghanaki 🐕

@DrewMoghanaki

3 years

Someone at UCLA just shared this study that was performed by investigators at UCLA. The conclusion speaks for itself. #lcsm #radonc

3

24

84

Drew Moghanaki 🐕

@DrewMoghanaki

2 years

The use of SBRT for oligoprogressive cancer often increases the MILEAGE of a current line of systemic therapy. Stated differently, it can also prevent "Systemic Therapy Escalation" @_ShankarSiva @IyengarPuneeth @jillfeldman4 #radonc

1

20

82

Drew Moghanaki 🐕

@DrewMoghanaki

10 months

Here is what happened to 12 patients with ALK, EGFR, or ROS1-driven brain metastases who were treated with upfront TKI instead of radiation therapy. #radonc #lcsm

6

19

84

Drew Moghanaki 🐕

@DrewMoghanaki

11 months

Just when I thought I knew everything about lung SBRT, one of our residents ( @MartinMaMDPhD ) teaches me this. #radonc

6

20

83

Drew Moghanaki 🐕

@DrewMoghanaki

3 months

MR-guided SBRT was associated with 100% local control in the 25 patients treated with a BED10 >100 Gy, single fraction, or fraction size >10 Gy/day. #radonc

2

22

84

Drew Moghanaki 🐕

@DrewMoghanaki

2 years

Timmerman is already in San Antonio, this time discussing his empathy for 2 Gy/day and how it needs help, like chemotherapy. #ASTRO22 #radonc

3

16

84

Drew Moghanaki 🐕

@DrewMoghanaki

9 months

A plain language summary of the Revised STARS trial that compared SABR to Surgery is now online. I'm curious if @RajaFlores is aware of it. #WCLC23 #radonc

4

26

84

Drew Moghanaki 🐕

@DrewMoghanaki

2 years

What will lung SBRT treatment planning look like after 4DCT is replaced with 5DCT? The first clinical experience with this breakthrough system was presented at #UKSABR22 on behalf of Dan Low. #radonc

4

20

82

Drew Moghanaki 🐕

@DrewMoghanaki

4 years

MYTH: Smoking causes lung cancer. Therefore we can prevent lung cancer by just focusing on getting everyone to quit. FACT: There are many reasons why people get lung cancer. Smoking is one, and we need more research to identify the others. #WorldLungCancerDay #lcam #lcsm

2

24

82

Drew Moghanaki 🐕

@DrewMoghanaki

2 years

From center stage at #ASTRO21 to writing her own editorial in the flagship #radonc journal, @jillfeldman4 continues to teach the world about the life-prolonging benefits of SBRT for oligometastatic disease. 🌎 @DavidSherMD @IASLC

9

20

81

Drew Moghanaki 🐕

@DrewMoghanaki

4 years

Are you serioiua? Even after I named you after the trial? #Valorie

9

1

80

Drew Moghanaki 🐕

@DrewMoghanaki

1 year

We now live in an era where upfront single-agent pembrolizumab can lead to 5y OS rates of 16-20% when tumors have any PD-L1 signal.

2

23

79

Drew Moghanaki 🐕

@DrewMoghanaki

4 months

VIEWRAY IS BACK!! #radonc

6

12

80

Drew Moghanaki 🐕

@DrewMoghanaki

1 year

A new analysis of the RTOG 0617 data by a team in Manchester may have just demystified the heart dose issue. Might this be a new avoidance structure to optimize outcomes? 🇬🇧 #radonc @finn_corinne

6

33

78

Drew Moghanaki 🐕

@DrewMoghanaki

8 months

He literally just finished residency in 2017. Six years to full Professor at UCLA is historic. #radonc

Amar Kishan

@AmarUKishan

8 months

Proud to share that I have been promoted to Professor! An achievement made possible only by working with exceptional colleagues, residents, and students at an exceptional place! @MSteinbergMD @UCLAJCCC @Ucla

69

9

312

3

6

78

Drew Moghanaki 🐕

@DrewMoghanaki

6 years

There are two types of beliefs in this world. Those that are informed, and those that are not. Please be nice to those who express their beliefs in the latter category.

7

10

74

Drew Moghanaki 🐕

@DrewMoghanaki

11 months

Radiation therapy technology is simply amazing.

2

20

76

Drew Moghanaki 🐕

@DrewMoghanaki

2 years

Happy Sunday everyone. While there is justified excitement around a 24% pCR rate with chemo-Nivo, we should not forget the 28% pCR rate with chemo-XRT using only 45 Gy. Thank you. #lungcancer #radonc @DoctorJSpicer @AltorkiNasser

8

15

75

Drew Moghanaki 🐕

@DrewMoghanaki

4 years

I wish that her mother, who was an amazing cancer researcher and mentor, was still with us to experience this moment.

Shyamala Gopalan - Wikipedia

en.m.wikipedia.org

Kamala Harris

@KamalaHarris

4 years

We did it, @JoeBiden .

89K

489K

3M

3

2

73

Drew Moghanaki 🐕

@DrewMoghanaki

4 years

A woman from Chicago living with lung cancer once again delivers an amazing talk that I will likely show to all future residents who rotate on my service. #ASCO20 #lcsm #radonc

2

20

73

Drew Moghanaki 🐕

@DrewMoghanaki

5 years

There's a major flaw with this commonly used curve which has been misleading the public for years whenever comparing IMRT to Proton therapy for prostate cancer. Can anyone see it? #radonc @aapmHQ

19

23

73

Drew Moghanaki 🐕

@DrewMoghanaki

1 year

This report might be the most misleading study ever published about lung SBRT. Poor-quality studies like this can only be accepted when a journal and its reviewers are asleep at the wheel or no longer care about minimum scientific standards. @JSurgRes 1/🧵

4

18

73

Drew Moghanaki 🐕

@DrewMoghanaki

5 years

As the world familiarizes itself with the SABR-COMET and OLIGOMEZ studies, @drdavidpalma reminded us at #SABR18 that we should also know the DUTCH phase II RCT that also showed an OS benefit with local ablative therapy.

8

29

71

Drew Moghanaki 🐕

@DrewMoghanaki

2 years

A pivotal study from @UTSW_RadOnc demonstrates what happened to 23 patients with oligometastatic Kidney Cancer who opted for SBRT instead of systemic drug therapy. #radonc

2

25

73

Drew Moghanaki 🐕

@DrewMoghanaki

5 years

A lung cancer survivor just shared that trying to get advice about Radiation Oncology from a Medical Oncologist is akin to it "asking a civil engineer to solve an electrical engineering problem". #lcsm #radonc @jillfeldman4

4

14

73

Drew Moghanaki 🐕

@DrewMoghanaki

1 year

Phrenic nerve injury is a known complication of thoracic surgery. A report from Stanford confirms it is now also associated with SBRT. #radonc

7

19

70

Drew Moghanaki 🐕

@DrewMoghanaki

1 year

Here is a study that could be more impactful if published in a surgical oncology journal. That's because surgeons are more likely to manage these patients. @sueyom #radonc

4

28

72

Drew Moghanaki 🐕

@DrewMoghanaki

5 years

I finally found it. The first RANDOMIZED study that demonstrated an OS benefit with radiotherapy for lung cancer. Completed at @VABronx with mesovoltage (200-260 kV), before discovery of the CT scanner, and when Roentgenologists planned the 4,000-5,000 r prescriptions. #radonc

4

17

71

Drew Moghanaki 🐕

@DrewMoghanaki

4 years

Here’s a bunch of people living with lung cancer. They spent the past two days with the NLCRT to make sure patients’ perspectives were considered by the panel assembled by the @AmericanCancer to develop a long term plan to #EndStigma . #lcsm

2

17

70

Drew Moghanaki 🐕

@DrewMoghanaki

7 months

Yes. #ESMO23

4

12

71

Drew Moghanaki 🐕

@DrewMoghanaki

4 years

"Should I hold the immune checkpoint inhibitor during stereotactic radiosurgery for brain metastases?" Another well-done study shows that it's not necessary. #radonc #lcsm @MarkMishraMD @JillRemickMD

5

22

70

Drew Moghanaki 🐕

@DrewMoghanaki

2 months

PACIFIC regimen improves OS for LA-NSCLC and now LS-SCLC. #radonc @QuadShotNews

Rami Manochakian MD, FASCO 🇺🇸🇸🇾CancerEducation

@RManochakian

2 months

🔥🚨 @OncoAlert Hot Off the Press BIG NEWS Press Release by @AstraZeneca #ADRIATIC phase 3 trial of #Durvalumab vs #Placebo after concurrent chemoradiotherapy in pts with limited-stage #SmallCell #LungCancer met dual primary endpoints of ⬆️ #OS & ⬆️ #PFS 👇🏼

7

45

100

3

25

68

Drew Moghanaki 🐕

@DrewMoghanaki

3 years

I just learned that this Canadian randomized study of SBRT successfully completed accrual. 🇨🇦 #radonc @SIRspecialists @_ShankarSiva

1

5

69

Drew Moghanaki 🐕

@DrewMoghanaki

4 months

10 years of experience at the University Hospital of Liège in Belgium (2010-2020) demonstrates the importance of >110% hotspots in lung SBRT plans. #radonc

2

33

69

Drew Moghanaki 🐕

@DrewMoghanaki

4 years

Halloween might be over, but I can’t stop worrying about this. @BrendonStilesMD

4

68

Drew Moghanaki 🐕

@DrewMoghanaki

4 years

While some are worried about treating 1 or 2 oligometastatic lesions, @drdavidpalma is helping the world figure out whether we should be treating 10 or even more instead. #radonc #lcsm @IyengarPuneeth @Docace911

6

18

69

Drew Moghanaki 🐕

@DrewMoghanaki

6 months

The same hospital that was founded by William Halsted more than a century ago is now led by a Radiation Oncologist, who is Dean and CEO of Johns Hopkins Medicine. #radonc @ASTRO_org @SocSurgOnc

Theodore DeWeese appointed next dean and CEO of Johns Hopkins Medicine

In 18 months as interim dean and CEO, he has set JHM on the path to financial transformation and launched a reimagination of the life and basic sciences at Hopkins

hub.jhu.edu

1

8

69

Drew Moghanaki 🐕

@DrewMoghanaki

1 year

In 2006, Chris Kelsey published a (must-read) study showing the patterns of locoregional failure after lung cancer surgery. 🇺🇸 In 2023, Tae Hoon Lee published a study showing the patterns of regional nodal recurrence after lung SBRT. 🇰🇷 #radonc

1

23

68